![]() From 2003-2019, Chris served as the Director of the Lymphoma Program at Winship Cancer Institute of Emory University where he also served as professor from 2016-2019. Flowers is an experienced physician and educator in the fields of medical oncology, hematology, molecular biology, and clinical and translational research. We believe that more sensitive MRD measurement will help improve patient care and we look forward to Chris's contributions in bringing Foresight's technology into clinical practice."ĭr. "Chris and I share a vision for improving cancer patient outcomes through earlier detection of minimal residual disease when intervention is most likely to be successful. "Chris has served on the frontlines of lymphoma treatment for years and brings a tremendous amount of clinical insight to our team," said Jake Chabon, Ph.D., co-founder and Chief Executive Officer of Foresight Diagnostics. His involvement in many of the B cell lymphoma clinical trials at MD Anderson places him at the forefront of progress in the treatment of lymphoma. ![]() Flowers takes an individualized approach to patient care by using molecular tests to identify unique cancer markers and tailoring treatment strategies specific to each patient. He currently serves as Chair and Professor in the Department of Lymphoma-Myeloma in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, TX, and is co-leader of MD Anderson's B-Cell Lymphoma Moon Shot® program. Flowers is an oncologist specializing in the treatment of B cell lymphoma and rare subtypes of lymphoma. Flowers, M.D., M.S., to its Scientific Advisory Board (SAB). ![]() Accomplished medical professor and physician with a successful career focused on treatment of B cell and rare lymphomasĪURORA, Colo., Ap/PRNewswire/ - Foresight Diagnostics today announced the appointment of Christopher R. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |